Larger group testing
The next step is to carry out longer testing of the treatment in much larger groups of people (sometimes thousands) with the specific condition, compared against an existing treatment or a placebo to see which works better, while still checking side effects.
If you are interested in any of these studies, please talk to your Respiratory Team.
Interstitial lung diseases
- TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial:
- The cause of idiopathic pulmonary fibrosis (IPF) is unknown, but there’s evidence suggesting that regular intake of anti-acid drugs like lansoprazole might slow its progression. These drugs reduce stomach acid, believed by some scientists to contribute to lung scarring. The TIPAL Study explores if adding lansoprazole slows lung function decline in IPF, assessing its impact on symptoms and quality of life compared to existing treatments.
- Click here for more info. CURRENTLY RECRUITING.
- Zephyrus II: A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis:
- The purpose of this study is to test whether Pamrevlumab will slow down the progression of your lung disease, IPF. Pamrevlumab works by interfering with neutralising Connective Tissue Growth Factor (CTGF), a protein that the body normally produces. Studies have shown increased activity/levels of CTGF in IPF patients, which might be an important factor in the disease progression. Recruitment has now closed. For further background reading on Pamrevlumab, click here. Now closed to recruitment.
See how your donations have contributed to our groundbreaking research
2024 ILD Research Report
Sign up!
Receive our latest research updates and news